Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada; Cancer Research Institute of Northern Alberta (CRINA), University of Alberta, Edmonton, AB T6G 2S2, Canada.
Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada; Cancer Research Institute of Northern Alberta (CRINA), University of Alberta, Edmonton, AB T6G 2S2, Canada; Edmonton Radiopharmaceutical Center, Cross Cancer Institute, Alberta Health Services, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada.
Nucl Med Biol. 2022 Jul-Aug;110-111:59-66. doi: 10.1016/j.nucmedbio.2022.04.005. Epub 2022 Apr 16.
Lanthanum radiometals are well positioned to serve as theranostic PET radiometals for targeted radionuclide therapy. The positron emitters La and La show promise to serve as unique PET imaging agents for Ac targeted alpha-particle therapy, the Ce/La pair has PET imaging potential with both Ac and Th, and La has potential in targeted Auger-Meitner electron therapy. With easily accessible cyclotron production routes, effective and efficient chemical separations, and robust chelation chemistry, these radionuclides are well poised for additional preclinical and clinical PET and targeted radionuclide therapy studies. This review summarizes recent advances in radiolanthanum production and preclinical applications that demonstrate the strong potential of these radionuclides in PET and targeted radionuclide therapy.
镧系放射性金属是作为治疗性 PET 放射性金属用于靶向放射性核素治疗的理想选择。正电子发射体镧和镧有望成为针对 Ac 的靶向α粒子治疗的独特 PET 成像剂，Ce/La 对具有针对 Ac 和 Th 的 PET 成像潜力，而 La 则具有靶向俄歇-迈特纳电子治疗的潜力。这些放射性核素具有易于获得的回旋加速器生产途径、有效的和高效的化学分离以及强大的螯合化学，为进一步的临床前和临床 PET 和靶向放射性核素治疗研究做好了充分准备。这篇综述总结了放射性镧生产和临床前应用的最新进展，这些进展证明了这些放射性核素在 PET 和靶向放射性核素治疗中的巨大潜力。
